Immature natural killer cells promote progression of triple-negative breast cancer
Science Translational Medicine · 08.03.2023 · 15 (686)
DOI: 10.1126/scitranslmed.abl4414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 08.03.2023. Verfasst von Gatha Thacker und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Natural killer (NK) cells are cytotoxic lymphocytes that accumulate within the tumor microenvironment and are generally considered to be antitumorigenic. Using single-cell RNA sequencing and functional analysis of multiple triple-negative breast cancer (TNBC) and basal tumor samples, we observed a unique subcluster of Socs3 high CD11b − CD27 − immature NK cells that were present only in TNBC samples. These tumor-infiltrating NK cells expressed a reduced cytotoxic granzyme signature and, in mice, were responsible for activating cancer stem cells through Wnt signaling. NK cell–mediated activation of these cancer stem cells subsequently enhanced tumor progression in mice, whereas depletion of NK cells or Wnt ligand secretion from NK cells by LGK-974 decreased tumor progression. In addition, NK cell depletion or inhibition of their function improved anti–programmed cell death ligand 1 (PD-L1) antibody or chemotherapy response in mice with TNBC. Furthermore, tumor samples from patients with TNBC and non-TNBC revealed that increased numbers of CD56 bright NK cells were present in TNBC tumors and were correlated to poor overall survival in patients with TNBC. Together, our findings identify a population of protumorigenic NK cells that may be exploited for both diagnostic and therapeutic strategies to improve outcomes for patients with TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
- Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.
- Department of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Department of Pathology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 33136, USA.
ORCID-Profile: Gatha Thacker, Rahul Debnath, Anupma Nayak, Barbara Susnik, Melinda M Boone, Qing Zhang, Susan B Kesmodel, Gokul M Das, Camila O Dos Santos, Rumela Chakrabarti
Förderung
- NCI NIH HHS
- NIA NIH HHS
Zitieren
APA
Thacker, G., Henry, S., Nandi, A., Debnath, R., Singh, S., Nayak, A., Susnik, B., Boone, M. M., Zhang, Q., Kesmodel, S. B., Gumber, S., Das, G. M., Kambayashi, T., Dos Santos, C. O., & Chakrabarti, R. (2023). Immature natural killer cells promote progression of triple-negative breast cancer. Science Translational Medicine, 15(686). https://doi.org/10.1126/scitranslmed.abl4414
Vancouver
Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, et al. Immature natural killer cells promote progression of triple-negative breast cancer. Science Translational Medicine. 2023;15(686). doi:10.1126/scitranslmed.abl4414
BibTeX
@article{Thacker2023,
author = {Thacker, Gatha and Henry, Samantha and Nandi, Ajeya and Debnath, Rahul and Singh, Snahlata and Nayak, Anupma and Susnik, Barbara and Boone, Melinda M and Zhang, Qing and Kesmodel, Susan B and Gumber, Sanjeev and Das, Gokul M and Kambayashi, Taku and Dos Santos, Camila O and Chakrabarti, Rumela},
title = {Immature natural killer cells promote progression of triple-negative breast cancer},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {686},
doi = {10.1126/scitranslmed.abl4414}
}
EUVIMED